NEW
YORK, Feb. 4, 2025 /PRNewswire/
-- Immunic, Inc. (Nasdaq: IMUX), a
biotechnology company developing a clinical pipeline of orally
administered, small molecule therapies for chronic inflammatory and
autoimmune diseases, today announced participation in the following
investor and scientific conferences in February:
- February 10-11: BIO CEO & Investor Conference 2025.
Daniel Vitt, Ph.D., Chief Executive
Officer of Immunic, will participate in one-on-one meetings at this
conference, taking place in New
York. Interested parties can request a meeting through the
BIO Partnering™ system or contact Jessica
Breu at: jessica.breu@imux.com.
- February 11-12: Oppenheimer
35th Annual Healthcare Life Sciences Conference. Dr. Vitt will
participate in a fireside chat at this virtual conference on
Wednesday, February 12 at
1:20 pm ET. A webcast will be
available on the "Events and Presentations" section of Immunic's
website at: https://ir.imux.com/events-and-presentations.
Additional team members, including Jason
Tardio, President and Chief Operating Officer, Glenn Whaley, Chief Financial Officer, and
Jessica Breu, Vice President
Investor Relations and Communications, will also be in attendance
to participate in one-on-one meetings at the conference. To
schedule a meeting, please contact your Oppenheimer representative
or Jessica Breu at:
jessica.breu@imux.com.
- February 19-22: 19th Congress
of ECCO (European Crohn's and Colitis Organisation). Members of
Immunic's medical, clinical and preclinical teams will attend this
congress in Berlin, Germany, where
two abstracts discussing clinical and preclinical data on IMU-856,
Immunic's orally available and systemically acting small molecule
modulator that targets Sirtuin 6 (SIRT6), will be presented as
digital oral presentations. The presentations will be accessible on
the "Events and Presentations" section of Immunic's website at:
https://ir.imux.com/events-and-presentations.
- Presentation Title: Promising Effects of IMU-856, an
Orally Available Epigenetic Modulator of Barrier Regeneration -
Biomarker Findings from a Phase 1 Clinical Study
- Presenting Author: Amelie
Schreieck, Ph.D., Senior Manager Biomarker Development,
Immunic
- Abstract Number: EC25-1515
- Presentation Number: DOP012
- Presentation Time: 5:57 pm
– 6:03 pm CET
- Session Name: Digital Oral Presentation (DOP) Session 2:
Clinical Trials II
- Session Date: February 20,
2025
- Session Hall: A8
- Presentation Title: Preclinical Characterization of
IMU-856, an Orally Available Epigenetic Modulator of Gut Barrier
Function and Regeneration
- Presenting Author: Martina
Wirth, Ph.D., Senior Manager Translational Pharmacology,
Immunic
- Abstract Number: EC25-1096
- Presentation Number: DOP116
- Presentation Time: 6:27 pm
– 6:33 pm CET
- Session Name: Digital Oral Presentation (DOP) Session
13: Basic Science in IBD
- Session Date: February 21,
2025
- Session Hall: A1
- February 25-27: 7th
Neuroimmunology Drug Development Summit. Hella Kohlhof, Ph.D., Chief Scientific Officer
of Immunic, will present an overview on Immunic's lead asset,
vidofludimus calcium (IMU-838), at this summit in Boston. The presentation will be accessible on
the "Events and Presentations" section of Immunic's website at:
https://ir.imux.com/events-and-presentations.
- Presentation Title: Vidofludimus Calcium (IMU-838)
Combines the Best of Two Worlds: Neuroprotection and Relapse
Prevention in Multiple Sclerosis
- Presentation Date: Thursday,
February 27, 2025
- Presentation Time: 12:10 pm
ET
- February 27 - March 1:
Americas Committee for Treatment and Research in Multiple
Sclerosis (ACTRIMS) Forum 2025. Members of Immunic's
medical, clinical and preclinical teams will attend this meeting in
West Palm Beach, Florida. Two
abstracts have been accepted for poster presentations, which will
be accessible on the "Events and Presentations" section of
Immunic's website at: https://ir.imux.com/events-and-presentations.
Additionally, the team will be available throughout the event at
booth #322.
- Poster Title: Baseline Characteristics Across Major
Clinical Trials in Progressive Multiple Sclerosis: Insights from
ORATORIO, EXPAND, MS-STAT2, HERCULES, and CALLIPER
- Presenting Author: Robert J.
Fox, Staff Neurologist, Mellon Center for Multiple
Sclerosis, Vice-Chair for Research, Neurological Institute,
Cleveland Clinic, Cleveland,
Ohio
- Abstract Number: 452
- Poster Number: P102
- Poster Session: 1
- Session Date: Thursday, February
27, 2025
- Session Time: 6:00 pm –
7:30 pm ET (even-numbered posters
present from 6:00-6:45 pm;
odd-numbered posters present from 6:45-7:30
pm)
- Poster Title: Vidofludimus Calcium Shows a Potential
Neuroprotective Function in Multiple Sclerosis through its Activity
on Nurr1 in Preclinical Models
- Presenting Author: Evelyn
Peelen, Ph.D., Head of Research, Immunic
- Abstract Number: 427
- Poster Number: P317
- Poster Session: 2
- Session Date: Friday, February
28, 2025
- Session Time: 6:00 pm –
7:30 pm ET (even-numbered posters
present from 6:00-6:45 pm;
odd-numbered posters present from 6:45-7:30
pm)
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a
biotechnology company developing a clinical pipeline of orally
administered, small molecule therapies for chronic inflammatory and
autoimmune diseases. The company's lead development program,
vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2
clinical trials for the treatment of relapsing and progressive
multiple sclerosis, respectively, and has shown therapeutic
activity in phase 2 clinical trials in patients suffering from
relapsing-remitting multiple sclerosis, progressive multiple
sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus
calcium combines neuroprotective effects, through its mechanism as
a first-in-class nuclear receptor related 1 (Nurr1) activator, with
additional anti-inflammatory and anti-viral effects, by selectively
inhibiting the enzyme dihydroorotate dehydrogenase (DHODH).
IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended
to restore intestinal barrier function and regenerate bowel
epithelium, which could potentially be applicable in numerous
gastrointestinal diseases, such as celiac disease, for which it is
currently in preparations for a phase 2 clinical trial. IMU-381,
which currently is in preclinical testing, is a next generation
molecule being developed to specifically address the needs of
gastrointestinal diseases. For further information, please visit:
www.imux.com.
Cautionary Statement Regarding Forward-Looking
StatementsThis press release contains "forward-looking
statements" that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, sufficiency of cash and cash
runway, expected timing, development and results of clinical
trials, prospects, plans and objectives of management are
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to management's and
employee's participation in investor and scientific conferences.
Immunic may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in the
forward-looking statements and you should not place undue reliance
on these forward-looking statements. Such statements are based on
management's current expectations and involve substantial risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the
COVID-19 pandemic, increasing inflation, impacts of the
Ukraine – Russia conflict and the conflict in the
Middle East on planned and ongoing
clinical trials, risks and uncertainties associated with the
ability to project future cash utilization and reserves needed for
contingent future liabilities and business operations, the
availability of sufficient financial and other resources to meet
business objectives and operational requirements, including the
ability to satisfy the minimum average price and trading volume
conditions required to receive funding in tranche 2 and 3 of the
January 2024 private placement, the
fact that the results of earlier preclinical studies and clinical
trials may not be predictive of future clinical trial results, the
protection and market exclusivity provided by Immunic's
intellectual property, risks related to the drug development and
the regulatory approval process and the impact of competitive
products and technological changes. A further list and descriptions
of these risks, uncertainties and other factors can be found in the
section captioned "Risk Factors," in the company's Annual Report on
Form 10-K for the fiscal year ended December
31, 2023, filed with the SEC on February 22, 2024, and in the company's
subsequent filings with the Securities and Exchange Commission.
Copies of these filings are available online at www.sec.gov or
ir.imux.com/sec-filings. Any forward-looking statement made in this
release speaks only as of the date of this release. Immunic
disclaims any intent or obligation to update these forward-looking
statements to reflect events or circumstances that exist after the
date on which they were made. Immunic expressly disclaims all
liability in respect to actions taken or not taken based on any or
all of the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-investor-and-scientific-conferences-in-february-302367302.html
SOURCE Immunic, Inc.
